- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00269958
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery
16 maj 2011 uppdaterad av: Janssen-Ortho Inc., Canada
A Double-Blind, Phase II, Placebo-Controlled Study to Determine the Safety and Efficacy of r-HuEPO in Reducing Transfusion Requirements in Patients Undergoing Total Hip Joint Replacement Surgery
The purpose of this study is to evaluate the safety and effectiveness of two different dosing schedules of epoetin alfa versus placebo for decreasing the need for blood transfusions and preventing the occurrence of severe anemia during the period of time around total hip replacement surgery.
Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
Studieöversikt
Detaljerad beskrivning
Major surgical procedures may require blood transfusions both during and after the operation.
Agents that can increase the rate of red blood cell production would reduce the need for blood transfusions and reduce the occurrence of anemia.
Epoetin alfa is a genetically engineered form of a natural hormone, erythropoietin, that is used to treat anemia by stimulating red blood cell production.
This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study in patients scheduled for total hip replacement surgery.
This study will assess the effectiveness of epoetin alfa (starting either 5 or 10 days before hip replacement surgery and continuing though 3 days after surgery) in reducing the need for blood transfusions and the occurrence of anemia during the time period surrounding surgery.
Hip replacement can be either the initial implant surgery or a second surgery on the same hip.
Eligible patients will be assigned to one of three treatment groups.
Group 1 will receive daily placebo injections under the skin for 14 days; Group 2 will receive a longer (14-day) course of daily epoetin alfa injections under the skin; and Group 3 will receive a shorter (9-day) course of daily epoetin alfa injections under the skin.
Patients in Groups 2 and 3 will receive 300 units of epoetin alfa per kilogram of body weight per day in each daily injection.
All patients will receive oral iron supplementation beginning 3 weeks prior to surgery and continuing through 1 week after surgery.
All patients will also receive low-dose coumadin (sodium warfarin) for 7 days after surgery to prevent clotting in the deep veins.
Effectiveness will be determined by the number of patients requiring transfusions and the number of patients who develop anemia (as measured by a hemoglobin level < 80 grams per liter).
Effectiveness will also be determined by the total number of transfusions required, changes in red blood cell variables (hemoglobin, hematocrit, the number of developing red blood cells (reticulocytes), changes in the iron stores in the patient's blood, intensity of nursing care required, well-being assessments (measures of pain, shortness of breath, and energy level), and the number of days in the hospital after surgery.
Safety evaluations will include the incidence of blood clots in the deep veins of the lower limbs, the incidence and severity of other adverse events, and changes in clinical laboratory test results and vital signs.
The study hypothesis is that patients treated with epoetin alfa before, during, and after hip replacement surgery will require fewer blood transfusions and have a reduced occurrence of anemia compared with patients treated with placebo, and that the shorter course of epoetin alfa dosing (9 days) is as effective as the longer epoetin alfa course (14 days).
300 units epoetin alfa per kilogram (U/kg) injected under the skin 5 or 10 days before surgery, the day of surgery, and 3 days after surgery; or placebo injection for 14 days.
Subjects receiving epoetin alfa for 5 days also received placebo for 5 days before starting epoetin alfa.
Studietyp
Interventionell
Inskrivning (Faktisk)
208
Fas
- Fas 2
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 85 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Patients scheduled for elective, first-time hip-replacement surgery or a second hip-replacement surgery (with surgery taking place within 48 hours of the scheduled time)
- having a baseline hemoglobin between 110 and 160 grams per liter
- with no significantly abnormal values for laboratory tests that would indicate an impaired ability to respond to epoetin alfa.
Exclusion Criteria:
- Patients with a primary hematologic disease
- having any clinically significant disease/dysfunction of the neurologic, pulmonary, endocrine, cardiovascular, gastrointestinal, or genitourinary systems
- who have had a seizure disorder in the past 5 years, or who are currently on anticonvulsant therapy
- having uncontrolled high blood pressure
- currently experiencing an ongoing blood loss
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
Proportion of patients needing blood transfusions; proportion of patients who develop anemia (defined as hemoglobin <80 grams per liter).
|
Sekundära resultatmått
Resultatmått |
---|
Number of blood units transfused; changes in red cell variables (hemoglobin, hematocrit, and reticulocyte counts); iron stores; nursing needs; scores on well-being tests; number days in hospital after surgery; deep vein clots and other adverse events
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Avslutad studie (Faktisk)
1 december 1991
Studieregistreringsdatum
Först inskickad
22 december 2005
Först inskickad som uppfyllde QC-kriterierna
22 december 2005
Första postat (Uppskatta)
26 december 2005
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
17 maj 2011
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
16 maj 2011
Senast verifierad
1 april 2010
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CR005887
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Anemi
-
Assistance Publique - Hôpitaux de ParisHar inte rekryterat ännuSvår aplastisk anemi | Idiopatisk aplastisk anemi | Måttlig aplastisk anemi som kräver transfusioner
-
National Heart, Lung, and Blood Institute (NHLBI)AvslutadAnemi, aplastisk | Anemi, hypoplastiskFörenta staterna
-
University of UtahNovartisAvslutadSvår aplastisk anemi | Måttlig aplastisk anemi | Mycket svår aplastisk anemiFörenta staterna
-
Peking University People's HospitalRekrytering
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes... och andra samarbetspartnersRekrytering
-
Federal Research Institute of Pediatric Hematology...Rekrytering
-
Jiangsu HengRui Medicine Co., Ltd.Avslutad
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School... och andra samarbetspartnersAvslutad
-
Jiangsu HengRui Medicine Co., Ltd.Avslutad
-
Nagoya UniversityOkändFörvärvad aplastisk anemi.Japan
Kliniska prövningar på epoetin alfa
-
Catholic University of the Sacred HeartSOFAR S.p.A.OkändGodartade, premaligna och maligna gynekologiska sjukdomar begränsade till bäckenetItalien
-
Xiangya Hospital of Central South UniversityOkänd
-
First Affiliated Hospital Xi'an Jiaotong UniversityRekrytering
-
Peking University Third HospitalRekryteringSköldkörtelögonsjukdomKina
-
University of EdinburghRekryteringAortastenos | Carcinoid syndrom | Kemoterapiinducerad systolisk dysfunktionStorbritannien
-
UMC UtrechtHar inte rekryterat ännuMetastaserande kolorektal cancer | Metastaserande cancer i levern
-
Sichuan Provincial People's HospitalRekryteringAldosteronproducerande adenomKina
-
Institute of Liver and Biliary Sciences, IndiaAvslutadAkut leversvikt | Akut vid kronisk leversviktIndien
-
Shanghai East HospitalChinese Academy of SciencesOkänd